drugset / Trial / NCT01466114

Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition

NCT01466114

Phase 2 Unknown 64 enrolled University of California, Los Angeles
RandomizedParallel-groupTriple-blindTreatment

Summary

Approximately 50% of people diagnosed with Multiple Sclerosis (MS) will develop problems with cognition. Currently, there are no FDA-approved treatments targeting cognitive function in Multiple Sclerosis. This trial will ascertain whether treatment with an estrogen pill, used in combination with standard MS anti-inflammatory drugs, can improve cognitive testing as compared to treatment with a placebo pill in combination with standard anti-inflammatory drugs in women with MS.

Timeline

Start
2011-10
Primary completion
2021-12
Completion
2022-04

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Estriol Unknown 8 mg Oral
Background Norethindrone Unknown 0.7 mg Oral